Microbiome and Fungal Drug Discovery
Par :Formats :
Disponible dans votre compte client Decitre ou Furet du Nord dès validation de votre commande. Le format ePub est :
- Compatible avec une lecture sur My Vivlio (smartphone, tablette, ordinateur)
- Compatible avec une lecture sur liseuses Vivlio
- Pour les liseuses autres que Vivlio, vous devez utiliser le logiciel Adobe Digital Edition. Non compatible avec la lecture sur les liseuses Kindle, Remarkable et Sony
, qui est-ce ?Notre partenaire de plateforme de lecture numérique où vous retrouverez l'ensemble de vos ebooks gratuitement
Pour en savoir plus sur nos ebooks, consultez notre aide en ligne ici
C'est si simple ! Lisez votre ebook avec l'app Vivlio sur votre tablette, mobile ou ordinateur :
- FormatePub
- ISBN8231736690
- EAN9798231736690
- Date de parution22/07/2025
- Protection num.pas de protection
- Infos supplémentairesepub
- ÉditeurWalzone Press
Résumé
The human mycobiome-the community of fungi residing in and on our bodies-has remained an underexplored frontier compared to the bacterial microbiome. However, growing evidence highlights the significant role of fungi in health and disease. This article delves into the fascinating world of the mycobiome, exploring its composition, ecological interactions with bacterial communities, and its influence on immune regulation and disease progression.
Special attention is given to the therapeutic potential of fungi, not just as pathogens but also as sources of bioactive compounds. Fungi have historically been prolific producers of antimicrobial, immunosuppressive, and anticancer agents. The review also outlines current approaches and challenges in fungal drug discovery, including culture-based and metagenomic techniques, as well as the promise of AI-driven tools in identifying novel fungal metabolites.
Through this lens, the piece underscores the untapped potential of the mycobiome in guiding next-generation drug discovery efforts.
Special attention is given to the therapeutic potential of fungi, not just as pathogens but also as sources of bioactive compounds. Fungi have historically been prolific producers of antimicrobial, immunosuppressive, and anticancer agents. The review also outlines current approaches and challenges in fungal drug discovery, including culture-based and metagenomic techniques, as well as the promise of AI-driven tools in identifying novel fungal metabolites.
Through this lens, the piece underscores the untapped potential of the mycobiome in guiding next-generation drug discovery efforts.
The human mycobiome-the community of fungi residing in and on our bodies-has remained an underexplored frontier compared to the bacterial microbiome. However, growing evidence highlights the significant role of fungi in health and disease. This article delves into the fascinating world of the mycobiome, exploring its composition, ecological interactions with bacterial communities, and its influence on immune regulation and disease progression.
Special attention is given to the therapeutic potential of fungi, not just as pathogens but also as sources of bioactive compounds. Fungi have historically been prolific producers of antimicrobial, immunosuppressive, and anticancer agents. The review also outlines current approaches and challenges in fungal drug discovery, including culture-based and metagenomic techniques, as well as the promise of AI-driven tools in identifying novel fungal metabolites.
Through this lens, the piece underscores the untapped potential of the mycobiome in guiding next-generation drug discovery efforts.
Special attention is given to the therapeutic potential of fungi, not just as pathogens but also as sources of bioactive compounds. Fungi have historically been prolific producers of antimicrobial, immunosuppressive, and anticancer agents. The review also outlines current approaches and challenges in fungal drug discovery, including culture-based and metagenomic techniques, as well as the promise of AI-driven tools in identifying novel fungal metabolites.
Through this lens, the piece underscores the untapped potential of the mycobiome in guiding next-generation drug discovery efforts.